What every woman needs to know about hormone therapy

Hormone therapy has one of the most misunderstood safety profiles in modern medicine. For nearly two decades, millions of women avoided a treatment that could have meaningfully improved their quality of life — all because of a study that was later shown to be deeply flawed. Dr. Sharon Malone, OB-GYN and author of Grown Woman Talk, breaks down what the science actually says and what every woman entering perimenopause or menopause should understand before making a decision.

Why hormone therapy got a bad reputation

The Women's Health Initiative (WHI) study, published in 2002, caused widespread fear about hormone therapy. Researchers reported a 26% increase in breast cancer risk among women taking a combination of synthetic estrogen (Premarin) and synthetic progestin (Provera/Prempro). The media amplified those numbers without context, and prescriptions dropped sharply overnight.

The problem was that the study had serious design flaws. The average participant was 63 years old — more than a decade past the onset of menopause. The study introduced hormones into cardiovascular systems that had already gone years without estrogen. This is not how hormone therapy works in clinical practice, and the risks observed in older women do not apply to women who start therapy at the time of menopause.

A reanalysis of the data showed that women who started estrogen within ten years of menopause had no increase in cardiovascular risk — and in many cases had a reduction in risk.

What the evidence actually supports

When initiated during the perimenopausal window (within 10 years of the last menstrual period or before age 60), hormone therapy offers several well-documented benefits:

• Cardiovascular protection: Estrogen preserves vascular elasticity and lowers LDL cholesterol. Women who start early see a meaningful reduction in heart disease risk.
• Bone density: Estrogen directly prevents the bone loss that accelerates during menopause and reduces the risk of osteoporosis and fractures.
• Cognitive function: Several studies suggest that early estrogen use is associated with a lower risk of Alzheimer's disease. Timing is critical — late initiation may not provide the same protection.
• Quality of life: Hot flashes, night sweats, sleep disruption, vaginal dryness, and mood instability are among the most debilitating symptoms of menopause. Hormone therapy remains the most effective treatment for all of them.

The notion that suffering through menopause is safer than treating it is not supported by the current evidence. As Dr. Malone puts it, the absence of treatment is also a choice — with its own consequences.

Choosing the right formulation

Not all hormone therapy is the same. The WHI used a specific combination of synthetic hormones — Premarin (conjugated equine estrogens) and Provera (synthetic progestin). Modern practice increasingly uses bioidentical hormones, which are structurally identical to the hormones the body produces naturally.

Estrogen delivery options include:

• Patches (transdermal): Bypasses the liver and avoids the blood clot risk associated with oral estrogen. Generally considered the safest route for most women.
• Gels and sprays: Similar to patches in terms of liver bypass.
• Oral tablets: Convenient but metabolized through the liver, which raises clotting risk slightly.
• Vaginal estrogen: Addresses local symptoms (dryness, discomfort, urinary urgency) without meaningful systemic absorption. Can be used long-term with a very low risk profile.

For women who have not had a hysterectomy, progesterone must be added to protect the uterine lining. Bioidentical progesterone (not synthetic progestin) is the preferred option — the evidence suggests it carries a lower breast cancer risk than medroxyprogesterone acetate.

When to start and what to watch for

The "timing hypothesis" is now one of the most important concepts in hormone therapy. The window of benefit is roughly the first 10 years after menopause or before age 60. Starting later, after estrogen receptors in the cardiovascular system have already adapted to low estrogen, may not provide the same benefits and may carry different risks.

Women considering hormone therapy should discuss the following with their clinician:

• Personal and family history of breast cancer, blood clots, or stroke: These are not always absolute contraindications, but they inform the risk-benefit calculation.
• Cardiovascular risk profile: Advanced diagnostics including lipid panels, coronary artery calcium scores, and inflammatory markers help assess baseline cardiovascular risk before starting therapy.
• Menopausal stage: Perimenopause and early postmenopause respond differently to hormone interventions.

FDA black box warning and updated guidance

In November 2025, the FDA removed the black box warning from hormone therapy labeling, reflecting the decades of accumulated evidence showing that the original WHI interpretation overstated risk. This is a significant regulatory signal and aligns with the clinical guidance from major medical societies including NAMS, the Endocrine Society, and ACOG.

For most healthy women under 60 who are within 10 years of menopause onset, the benefits of hormone therapy outweigh the risks. The conversation between a woman and her clinician should be based on current evidence, individual risk factors, and a clear explanation of the actual numbers — not decades-old fear.